China's medical products administrator approved Jiangsu CoWin Biotech's (SHA:688426) influenza A/B and respiratory syncytial virus nucleic acid detection kit, according to a Tuesday filing with the Shanghai Stock Exchange.
The kits use fluorescence polymerase chain reaction methods through swab samples from the pharynx, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.